Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1629229-37-3
Molecular formula
C16H15FN6OS
Molecular weight
358.4 g/mol
Drug class
Neurokinin 3 Receptor Antagonist
Mechanism of action
Neurokinin 3 Receptor Antagonists [MoA]
Indications / reported uses
Hot Flashes
moderate to severe vasomotor symptoms due to menopause
Drug class, mechanism of action and general use cases
Drug class
Neurokinin 3 Receptor Antagonist
Mechanism of action
Neurokinin 3 Receptor Antagonists [MoA]
General use cases
Hot Flashes
moderate to severe vasomotor symptoms due to menopause
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
Assessment scope
Project-specific PDE/ADE and OEL/OEB support
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Fezolinetant PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fezolinetant Permitted Daily Exposure (PDE) report (the Fezolinetant PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fezolinetant Occupational Exposure Limit (OEL) report (the Fezolinetant OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.